Jiangsu Hengrui Pharmaceuticals600276.SHValuation Analysis

As of Oct 19, 2026, Jiangsu Hengrui Pharmaceuticals (600276.SH) trades at a P/E of 40.10x, P/B of 4.81x, P/S of 10.00x, and a dividend yield of 0.43%.
Longitudinal percentile comparison: P/E sits at the 3rd percentile over the trailing 10Y window (vs. 10th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 11th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 53rd percentile within its industry and the 53rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.75%, ranking at the 97th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 1.3 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 0.43% comes from cash dividends, with an implied ~0.32% from buybacks — a fairly balanced mix of both channels. Jiangsu Hengrui Pharmaceuticals operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.